Market research
AYTU Aytu BioScience Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 25M
- P/E ratio
- Not available
- Analyst target
- 9.5
- Dividend yield
- Not available
- Beta
- 0.26
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US0547548588
- Market cap
- 25M
- P/E ratio
- Not available
- Analyst target
- 9.5
- Dividend yield
- Not available
- Beta
- 0.26
About
About Aytu BioScience Inc
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AYTU discussion.
5 years, 4 months ago
Aytu Biopharma, Inc is currently in a long term downtrend where the price is trading 36.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.5.
Aytu Biopharma, Inc's total revenue rose by 377.0% to $15M since the same quarter in the previous year.
Its net income has dropped by 4345.9% to $-10M since the same quarter in the previous year.
Finally, its free cash flow grew by 72.4% to $-3M since the same quarter in the previous year.
Based on the above factors, Aytu Biopharma, Inc gets an overall score of 3/5.